Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease-Reference-Cited by-同舟云学术

Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease

Published:2019-01 Issue:1 Volume:25 Page:47-55
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Zhang Ran,Lu Xuan,Wang Huafang,You Yong,Zhong Zhaodong,Zang Sibin,Zhang Chun,Shi Wei,Li Junying,Wu Qiuling,Fang Jun,Xia Linghui

Funder

National Natural Sciences foundation of China

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference37 articles.

1. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia;Leung;Blood,2012

2. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission;Araki;J Clin Oncol,2016

3. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia;Buckley;Bone Marrow Transplant,2013

4. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation;Walter;Leukemia,2015

5. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia;Kayser;Blood Cancer J,2016

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre‐transplant minimal residual disease on outcomes in high‐risk acute lymphoblastic leukemia patients in complete remission;Cancer Medicine;2024-01

2. Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia;Leukemia & Lymphoma;2023-09-21

3. Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing auto‐HSCT: An open‐label, multicenter, randomized phase 3 trial;American Journal of Hematology;2023-01

4. Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia;Frontiers in Immunology;2022-11-15

5. Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation;Frontiers in Immunology;2022-09-15